Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes
- PMID: 16189125
- PMCID: PMC1251552
- DOI: 10.1128/AAC.49.10.4372-4374.2005
Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes
Abstract
The antistaphylococcal activity of ceftobiprole was compared with those of cefuroxime, linezolid, and moxifloxacin by using the agar dilution method. Apart from three strains with small-colony variant phenotypes, all Staphylococcus aureus isolates tested were inhibited by < or =2 microg/ml of ceftobiprole. This compound exhibited an excellent antistaphylococcal activity, comparable to that of linezolid.
References
-
- Baumert, N., C. von Eiff, F. Schaaff, G. Peters, R. A. Proctor, and H. G. Sahl. 2002. Physiology and antibiotic susceptibility of Staphylococcus aureus small colony variants. Microb. Drug Resist. 8:253-260. - PubMed
-
- CLSI (formerly NCCLS). 2005. Performance standards for antimicrobial susceptibility testing; 15th informational supplement (M100-S15). CLSI, Wayne, Pa.
-
- Deshpande, L., P. R. Rhomberg, T. R. Fritsche, H. S. Sader, and R. N. Jones. 2004. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary gram-positive and gram-negative isolates. Diagn. Microbiol. Infect. Dis. 50:73-75. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases